Kawasaki disease, also known as mucocutaneous lymph node syndrome, is a self-limiting disease but is an acute systemic vasculitis commonly seen in infants and children under the age of 5. The primary clinical manifestations include non-suppurative cervical lymphadenopathy, oral mucosal lesions, conjunctival congestion, prolonged fever, polymorphous rash, and hard swelling of the hands and feet with fingertip desquamation. Cardiovascular damage is the most severe complication of Kawasaki disease and can lead to coronary artery aneurysms and coronary artery dilation. If Kawasaki disease is not treated promptly, the incidence of developing coronary artery aneurysms is 15%-25%, making Kawasaki disease one of the most common causes of acquired heart disease in infants and young children. Therefore, timely treatment of Kawasaki disease is crucial, generally involving anti-inflammatory treatment, immune support, and symptomatic management. If there is no concomitant coronary artery damage, treatment involves symptomatic management. If there is coronary artery damage, the treatment duration will be longer and regular follow-up is necessary. The course of the disease can extend over months or even years, thus treatment of Kawasaki disease needs to be tailored based on the individual's condition and clinical symptoms.